Intrinsic value of Lazard US Equity Concentrated Portfolio (LEVIX)
Live fair value data for Lazard US Equity Concentrated Portfolio (LEVIX) is currently unavailable. Please check again shortly.
Current Price: $432.00
Valuation: Overvalued
Confidence: 4.0/10
Visual Bar
This intrinsic value is calculated using 5 different models based on projected revenue growth, profit margins, and a standard discount rate.
Is Lazard US Equity Concentrated Portfolio (LEVIX) undervalued or overvalued?
Based on the current model output, Lazard US Equity Concentrated Portfolio appears to be overvalued with a downside of 5.00%.
Fair value vs market price — Lazard US Equity Concentrated Portfolio (LEVIX)
Unlock premium access to view the live fair value comparison against current market price for LEVIX.
Frequently Asked Questions - LEVIX
How is LEVIX intrinsic value estimated?
We combine revenue growth, discount rate, and terminal growth assumptions to estimate a fair value range for LEVIX.
Is LEVIX undervalued or overvalued right now?
LEVIX is currently shown as overvalued based on the difference between market price and intrinsic value.
How should I use the confidence score?
The confidence score (0 to 10) indicates model certainty from available inputs. Higher values suggest stronger model consistency, not a guarantee of returns.
Related companies — intrinsic value
Peers for LEVIX: open their intrinsic value pages.
- AAgilent Technologies, Inc.
- WILNXWilliam Blair International Leaders Fund Class N Shares
- GGOAXGoldman Sachs Mid Cap Growth Fund Class A Shares
- BMDSXBaird Mid Cap Growth Fund - Investor Class
- EEni S.p.A.
- LEVOXLazard US Equity Concentrated Portfolio Open Shares
- SFAAXAllspring Index Asset Allocation Fund Class A
- PLCIXVoya Large-Cap Growth Fund - I